celecoxib has been researched along with Carcinoma, Pancreatic Ductal in 7 studies
Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 6.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
| "Celecoxib treatment suppressed FGF-2 and FGFR-2 expression and decreased MMP-2, MMP-9 and p-ERK expression in the PANC-1 cells." | 5.43 | Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells. ( Dong, L; Li, J; Luo, M; Shang, B; Wang, Y, 2016) |
| " In this study, we show that a novel Mucin-1 (MUC1)-based vaccine in combination with a cyclooxygenase-2 inhibitor (celecoxib), and low-dose chemotherapy (gemcitabine) was effective in preventing the progression of preneoplastic intraepithelial lesions to invasive pancreatic ductal adenocarcinomas." | 3.75 | Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. ( Arefayene, M; Basu, GD; Bradley, JM; De Petris, G; Mukherjee, P; Skaar, T; Subramani, DB; Tinder, TL, 2009) |
| "Capecitabine was administered at a dose of 1,000 mg/m(2) b." | 2.74 | Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009) |
| "The progression and metastasis of pancreatic ductal adenocarcinoma (PDAC) is highly dependent on the tumour microenvironment." | 1.51 | Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. ( Bai, X; Chen, Q; Chen, Y; Dang, X; Fu, Q; Liang, T; Lou, Y; Wang, J; Wei, T; Yang, J; Ye, M; Zhang, J; Zhang, Q; Zhang, X, 2019) |
| "Celecoxib treatment suppressed FGF-2 and FGFR-2 expression and decreased MMP-2, MMP-9 and p-ERK expression in the PANC-1 cells." | 1.43 | Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells. ( Dong, L; Li, J; Luo, M; Shang, B; Wang, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Q | 1 |
| Wang, J | 1 |
| Zhang, Q | 1 |
| Zhang, J | 2 |
| Lou, Y | 1 |
| Yang, J | 1 |
| Chen, Y | 1 |
| Wei, T | 1 |
| Fu, Q | 1 |
| Ye, M | 1 |
| Zhang, X | 1 |
| Dang, X | 1 |
| Liang, T | 1 |
| Bai, X | 1 |
| Li, J | 1 |
| Luo, M | 1 |
| Wang, Y | 2 |
| Shang, B | 1 |
| Dong, L | 1 |
| Colby, JK | 1 |
| Klein, RD | 1 |
| McArthur, MJ | 1 |
| Conti, CJ | 1 |
| Kiguchi, K | 1 |
| Kawamoto, T | 1 |
| Riggs, PK | 1 |
| Pavone, AI | 1 |
| Sawicki, J | 1 |
| Fischer, SM | 1 |
| Mukherjee, P | 1 |
| Basu, GD | 1 |
| Tinder, TL | 1 |
| Subramani, DB | 1 |
| Bradley, JM | 1 |
| Arefayene, M | 1 |
| Skaar, T | 1 |
| De Petris, G | 1 |
| Pino, MS | 1 |
| Milella, M | 1 |
| Gelibter, A | 1 |
| Sperduti, I | 1 |
| De Marco, S | 1 |
| Nuzzo, C | 1 |
| Bria, E | 1 |
| Carpanese, L | 1 |
| Ruggeri, EM | 1 |
| Carlini, P | 1 |
| Cognetti, F | 1 |
| Hill, R | 1 |
| Li, Y | 1 |
| Tran, LM | 1 |
| Dry, S | 1 |
| Calvopina, JH | 1 |
| Garcia, A | 1 |
| Kim, C | 1 |
| Donahue, TR | 1 |
| Herschman, HR | 1 |
| Wu, H | 1 |
| Gregor, JI | 1 |
| Kilian, M | 1 |
| Heukamp, I | 1 |
| Kiewert, C | 1 |
| Kristiansen, G | 1 |
| Schimke, I | 1 |
| Walz, MK | 1 |
| Jacobi, CA | 1 |
| Wenger, FA | 1 |
1 trial available for celecoxib and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2009 |
6 other studies available for celecoxib and Carcinoma, Pancreatic Ductal
| Article | Year |
|---|---|
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celecoxib; Ce | 2019 |
Celecoxib suppresses fibroblast growth factor-2 expression in pancreatic ductal adenocarcinoma PANC-1 cells.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Line, Tumor; Cell Prolifera | 2016 |
Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Transformation, Neoplastic | 2008 |
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Antibodies; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Celecoxib; Cyclo | 2009 |
Cell intrinsic role of COX-2 in pancreatic cancer development.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Membrane; Cyclooxygenase 2; Disease Models, A | 2012 |
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster.
Topics: Animals; Carcinoma, Pancreatic Ductal; Celecoxib; Cricetinae; Cyclooxygenase Inhibitors; Dinoproston | 2005 |